Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/07/25
End: 09/30/25
Due: 09/30/26
Phase: N/A
Priority: Normal
Start: 01/28/25
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 08/08/24
End: 06/06/25
Due: 06/06/26
Phase: N/A
Priority: Normal
Start: 03/18/23
End: 03/06/24
Due: 03/06/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | NCT06771115 | Zomagen Biosciences Ltd. | user2@example.com | None | 2025-01-07 | 2025-09-30 | 2026-09-30 | - | - | 2025-07-14 |
| An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | NCT06836232 | Zomagen Biosciences Ltd. | user2@example.com | None | 2025-01-28 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |
| Phase 2a Study of VTX3232 in Parkinson's Disease | NCT06556173 | Zomagen Biosciences Ltd. | user2@example.com | None | 2024-08-08 | 2025-06-06 | 2026-06-06 | - | - | 2025-07-14 |
| A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome | NCT05812781 | Zomagen Biosciences Ltd. | user2@example.com | None | 2023-03-18 | 2024-03-06 | 2025-03-06 | - | - | 2025-07-14 |